PMID- 23125920
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121106
LR  - 20220318
IS  - 2090-0732 (Electronic)
IS  - 2090-0724 (Print)
IS  - 2090-0724 (Linking)
VI  - 2012
DP  - 2012
TI  - Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological 
      Perspective.
PG  - 381713
LID - 10.1155/2012/381713 [doi]
LID - 381713
AB  - In recent years the incretin therapies have provided a new treatment option for 
      patients with type 2 diabetes mellitus (T2DM). The incretin therapies focus on 
      the increasing levels of the two incretin hormones, glucagon-like peptide 1 
      (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This results in 
      increased glucose dependent insulin synthesis and release. GLP-1 receptor 
      agonists such as liraglutide and exenatide exert an intrinsic biological effect 
      on GLP-1 receptors directly stimulating the release of insulin from pancreatic 
      beta cells. DPP-4 inhibitors such as sitagliptin and linagliptin prevent the 
      inactivation of endogenous GLP-1 and GIP through competitive inhibition of the 
      DPP-4 enzyme. Both incretin therapies have good safety and tolerability profiles 
      and interact minimally with a number of medications commonly prescribed in T2DM. 
      This paper focuses on the pharmacological basis by which the incretin therapies 
      function and how this knowledge can inform and benefit clinical decisions. Each 
      individual incretin agent has benefits and pitfalls relating to aspects such as 
      glycaemic and nonglycaemic efficacy, safety and tolerability, ease of 
      administration, and cost. Overall, a personalized medicine approach has been 
      found to be favourable, tailoring the incretin agent to benefit and suit 
      patient's needs such as renal impairment (RI) or hepatic impairment (HI).
FAU - Brown, Dominique Xavier
AU  - Brown DX
AD  - Department of Diabetes, University Hospital Llandough, Cardiff CF64 2XX, UK.
FAU - Evans, Marc
AU  - Evans M
LA  - eng
PT  - Journal Article
DEP - 20121018
PL  - United States
TA  - J Nutr Metab
JT  - Journal of nutrition and metabolism
JID - 101526296
PMC - PMC3483791
EDAT- 2012/11/06 06:00
MHDA- 2012/11/06 06:01
PMCR- 2012/10/18
CRDT- 2012/11/06 06:00
PHST- 2012/08/07 00:00 [received]
PHST- 2012/09/21 00:00 [accepted]
PHST- 2012/11/06 06:00 [entrez]
PHST- 2012/11/06 06:00 [pubmed]
PHST- 2012/11/06 06:01 [medline]
PHST- 2012/10/18 00:00 [pmc-release]
AID - 10.1155/2012/381713 [doi]
PST - ppublish
SO  - J Nutr Metab. 2012;2012:381713. doi: 10.1155/2012/381713. Epub 2012 Oct 18.